<!doctype html>
<html lang="en">

<head>
    <!-- Charset + Viewport -->
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1, viewport-fit=cover" />
    <!-- Indexing & Privacy -->
    <meta name="robots" content="noindex, nofollow" />
    <meta name="referrer" content="strict-origin-when-cross-origin" />
    <!-- Theming & UX -->
    <meta name="color-scheme" content="light dark" />
    <meta name="theme-color" content="#003366" />
    <meta name="format-detection" content="telephone=no, address=no, email=no" />
    <meta name="apple-mobile-web-app-capable" content="yes" />
    <meta name="apple-mobile-web-app-status-bar-style" content="default" />
    <meta name="mobile-web-app-capable" content="yes" />
    <!-- Title + Description -->
    <title>MDT Correlation Request - James Saint</title>
    <meta name="description" content="MDT correlation request linking subtle brainstem T2 observation with clinical picture and prior right cerebral infarct." />
    <!-- Open Graph -->
    <meta property="og:title" content="MDT Correlation Request - James Saint" />
    <meta property="og:description" content="MDT correlation request linking subtle brainstem T2 observation with clinical picture and prior right cerebral infarct." />
    <meta property="og:type" content="article" />
    <meta property="og:url" content="" />
    <meta property="og:site_name" content="James Saint" />
    <meta property="og:locale" content="en_GB" />
    <meta property="og:image" content="https://jamessaint.github.io/images/seed-of-life-gold-default.png" />
    <meta property="og:image:width" content="1200" />
    <meta property="og:image:height" content="630" />
    <!-- Twitter Cards -->
    <meta name="twitter:card" content="summary_large_image" />
    <meta name="twitter:title" content="MDT Correlation Request - James Saint" />
    <meta name="twitter:description" content="MDT correlation request linking subtle brainstem T2 observation with clinical picture and prior right cerebral infarct." />
    <meta name="twitter:image" content="https://jamessaint.github.io/images/seed-of-life-gold-default.png" />
    <!-- App Icons + Manifest -->
    <link rel="apple-touch-icon" sizes="180x180" href="https://jamessaint.github.io/images/icons/apple-touch-icon.png" />
    <link rel="icon" type="image/png" sizes="32x32" href="https://jamessaint.github.io/images/icons/favicon-32x32.png" />
    <link rel="icon" type="image/png" sizes="16x16" href="https://jamessaint.github.io/images/icons/favicon-16x16.png" />
    <link rel="manifest" href="https://jamessaint.github.io/site.webmanifest" />
    <link rel="mask-icon" href="https://jamessaint.github.io/images/icons/safari-pinned-tab.svg" color="#003366" />
    <meta name="msapplication-TileColor" content="#003366" />
    <!-- Preconnect/DNS Prefetch for performance -->
    <link rel="preconnect" href="https://cdn.jsdelivr.net" crossorigin>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link rel="dns-prefetch" href="//cdn.jsdelivr.net">
    <link rel="dns-prefetch" href="//fonts.googleapis.com">
    <link rel="dns-prefetch" href="//fonts.gstatic.com">
    <!-- CSS Framework + Fonts -->
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.3/dist/css/bootstrap.min.css" rel="stylesheet" />
    <link href="https://fonts.googleapis.com/css2?family=Montserrat:wght@300;400;600;700&display=swap" rel="stylesheet">
    <link href="https://jamessaint.github.io/medical/global_styles.css" rel="stylesheet" />
    <!-- Mild Content Security Policy -->
    <meta http-equiv="Content-Security-Policy" content="
    default-src 'self';
    img-src 'self' https: data:;
    style-src 'self' 'unsafe-inline' https://fonts.googleapis.com https://cdn.jsdelivr.net;
    font-src 'self' https://fonts.gstatic.com data:;
    connect-src 'self';
    frame-ancestors 'none';
    base-uri 'self';
    form-action 'self'
  ">
    <!-- Structured Data -->
    <script type="application/ld+json">
    {
        "@context": "https://schema.org",
        "@type": "WebPage",
        "name": "MDT Correlation Request - James Saint",
        "url": "",
        "description": "MDT correlation request linking subtle brainstem T2 observation with clinical picture and prior right cerebral infarct.",
        "inLanguage": "en-GB",
        "isPartOf": { "@type": "WebSite", "name": "James Saint", "url": "https://jamessaint.github.io/" }
    }
    </script>
</head>

<body>
    <main class="content">
        <nav aria-label="breadcrumb">
            <ol class="breadcrumb">
                <li class="breadcrumb-item"><a href="/medical">Medical Home</a></li>
                <li class="breadcrumb-item"><a href="/medical/neurological">Neurological</a></li>
                <li class="breadcrumb-item active" aria-current="page">Correlation Request</li>
            </ol>
        </nav>
        <section id="mdt-executive-intro" class="section card-like">
            <h2>Executive Summary - For MDT Review</h2>
            <p>
                This page presents a concise correlation request with: (1) clinical context, (2) axial T2 observation with figures,
                (3) specific questions for MDT correlation, and (4) a brief symptom overview table.
            </p>
            <p class="meta">
                Full case index (labs, imaging, correspondence, medication trials) is available here:
                <a href="https://jamessaint.github.io/medical/neurological/" target="_blank" rel="noopener">Neurological Records</a>.
            </p>
        </section>
        <header class="mb-3">
            <h1 class="mb-2">MDT Correlation Request</h1>
        </header>
        <section class="section card-like">
            <p>
                <strong>Subject:</strong> Correlation request - subtle brainstem T2 observation and clinical picture. <br>
                <strong>Date:</strong> 8 October 2025
            </p>
            <p>Dear Dr. Malik and MDT,</p>
            <p>Thank you very much for reviewing my case. I appreciate I’m not a clinician, but given my background in Machine Learning and pattern recognition, I’ve reviewed my scans to better understand the medical discussion. My intention is not to interpret findings but to clearly flag what appears to me as a possible area for expert correlation.</p>
        </section>
        <section class="section card-like">
            <h2>Context</h2>
            <p>For clarity, here is the current clinical context as understood from the most recent consultation and imaging:</p>
            <ul>
                <li>Original impression: <strong>right cerebellar infarct of uncertain cause</strong>, identified following acute onset of left-sided hemisensory neuropathic pain after the second <strong>AstraZeneca COVID-19 vaccine</strong>.</li>
                <li><strong>Vascular work-up negative</strong>: CT angiogram and bubble echocardiogram ruled out paradoxical embolic source.</li>
                <li><strong>CSF clear</strong>: lumbar puncture showed no oligoclonal bands or inflammatory markers.</li>
                <li>Previous <strong>C5/6 cervical signal</strong> change on 1.5 T MRI is now viewed as <strong>non-reproducible</strong> on 3 T imaging and not supportive of active myelitis.</li>
                <li>Dr Malik’s current working diagnosis: a <strong>small, radiologically indiscernible right-sided brainstem stroke</strong> within the same arterial territory as the cerebellar infarct, likely explaining the persistent <strong>left-sided sensory disturbance and occipital pain</strong>.</li>
                <li>Given the <strong>temporal relationship to vaccination</strong> and absence of alternative vascular risk factors, a <strong>vaccine-related thromboembolic mechanism</strong> is regarded as more plausible than other causes.</li>
                <li><strong>Central post-stroke pain</strong> remains a leading explanation for ongoing neuropathic symptoms.</li>
                <li><strong>MDT review scheduled</strong> at Cromwell Hospital on <strong>5 November 2025</strong> for collective evaluation of the brainstem–cerebellar findings and treatment response.</li>
                <li><strong>Trial of Carbamazepine (Tegretol)</strong> initiated: 100 mg once daily for 2 weeks, increasing to 100 mg twice daily, to assess modulation of neuropathic pain prior to MDT feedback.</li>
            </ul>
        </section>
        <section class="section card-like">
            <h2>Observation (Axial T2)</h2>
            <p>On review of the axial T2 series, I noted a very subtle focus of increased signal within the brainstem region on one slice. I fully appreciate this may represent artefact, normal variation, or partial-volume effect, and I would be grateful for your expert correlation as to whether this might align with the current clinical hypothesis.</p>
            <div class="row g-3 mt-2">
                <div class="col-12 col-md-6">
                    <figure>
                        <img src="images/MRI_Combined_CerebralInfarct_and_Brainstem.png" alt="Composite: right cerebral context and brainstem slice" class="img-fluid rounded border">
                        <figcaption><strong>Figure 1.</strong> Composite providing context; right cerebral infarct alongside the flagged brainstem slice.</figcaption>
                    </figure>
                </div>
                <div class="col-12 col-md-6">
                    <figure>
                        <img src="images/MRI_Axial_Brainstem_Focus.jpeg" alt="Axial T2 — subtle brainstem hyperintensity (annotated)" class="img-fluid rounded border">
                        <figcaption><strong>Figure 2.</strong> Axial T2 slice highlighting the subtle hyperintensity focus within the brainstem region (for MDT verification).</figcaption>
                    </figure>
                </div>
            </div>
        </section>
        <section class="section card-like">
            <h2>Why I believe it merits correlation</h2>
            <p>I’m including the following purely to explain why, as a patient, I felt it might warrant your expert review:</p>
            <ul>
                <li>The focal signal appears qualitatively brighter than adjacent parenchyma on that slice, without obvious mass effect.</li>
                <li>If real, its location could plausibly intersect pathways relevant to the left-sided symptoms (to be confirmed by you).</li>
                <li>This aligns with the current clinical hypothesis that a small brainstem event could explain the presentation.</li>
            </ul>
            <p class="note mb-0"><strong>Important:</strong> I recognise common pitfalls in this region (pulsation, flow, susceptibility, and partial volume). I’m explicitly asking for radiology correlation to confirm or exclude this as an artefact.</p>
        </section>
        <section class="section card-like">
            <h2>Specific requests to the MDT</h2>
            <ol>
                <li>Please verify whether the subtle T2 focus seen in <em>Figure&nbsp;2</em> represents a true parenchymal signal change versus artefact.</li>
                <li>If helpful, correlate with <strong>DWI/ADC</strong> and <strong>FLAIR</strong> on the same level, and consider comparison with any prior brain MRIs for stability or evolution.</li>
                <li>Advise on whether a <strong>targeted brainstem protocol</strong> (thin‑slice axial, reduced EPI distortion DWI, and SWI as indicated) would be informative if ambiguity remains.</li>
                <li>Comment on concordance (or not) with the left‑sided symptoms and the previously noted right cerebral infarct.</li>
            </ol>
            <p class="note mb-0">I completely understand the team’s workload, and my intention is only to support the ongoing diagnostic process by ensuring potential details aren’t missed.</p>
        </section>
        <section class="section card-like">
            <h2>Closing</h2>
            <p>I’m offering these observations in the spirit of collaboration and transparency. I would be deeply grateful for your opinion on whether this subtle finding could plausibly fit the current brainstem hypothesis, or if it is more likely to represent an artefact or normal variation. Thank you very much for your continued care and multidisciplinary coordination.</p>
            <p>With appreciation,<br>
                <strong>James Saint</strong></p>
        </section>
        <section id="mast-cell-activation-differential" class="section card-like">
            <h2>Mast Cell Activation Differential & Further Investigations Requested</h2>
            <p>
                Following comprehensive autoimmune, infectious, and immunoglobulin screening, all of which returned negative or within reference range,
                a <strong>mast cell activation–mediated process</strong> remains a plausible untested contributor to the multisystem symptoms observed
                (neuropathic pain, pruritus, flushing, and autonomic instability).
            </p>
            <p>
                Given the pattern of <strong>allergic-type reactions to multiple medications</strong> and autonomic dysregulation despite normal ANA, ENA, ANCA,
                complement, and immunoglobulin profiles, it is reasonable to evaluate for <strong>Mast Cell Activation Syndrome (MCAS)</strong> as part of the ongoing
                differential.
            </p>
            <h3>Recommended Investigations</h3>
            <div class="table-wrap">
            <table>
                <thead>
                    <tr>
                        <th>Test</th>
                        <th>Purpose</th>
                        <th>Specimen</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Serum Tryptase</strong></td>
                        <td>Baseline and repeat during a flare to detect mast cell mediator release.</td>
                        <td>Blood (serum)</td>
                    </tr>
                    <tr>
                        <td><strong>24-hr Urinary N-Methylhistamine</strong></td>
                        <td>Measures histamine metabolite to assess systemic mast-cell activity.</td>
                        <td>Urine (24-hour collection)</td>
                    </tr>
                    <tr>
                        <td><strong>24-hr Urinary Prostaglandin D₂ & 11-β-PGF₂α</strong></td>
                        <td>Detects mast-cell–derived prostanoid release contributing to inflammation or pain.</td>
                        <td>Urine (24-hour collection)</td>
                    </tr>
                    <tr>
                        <td><strong>24-hr Urinary Leukotriene E₄</strong></td>
                        <td>Assesses eicosanoid pathway activation in hypersensitivity or MCAS.</td>
                        <td>Urine (24-hour collection)</td>
                    </tr>
                    <tr>
                        <td><strong>Chromogranin A</strong></td>
                        <td>Optional marker for neuroendocrine activation overlap.</td>
                        <td>Blood (serum)</td>
                    </tr>
                </tbody>
            </table>
        </div>
            <h3>Clinical Rationale</h3>
            <p>
                Mast cell activation may bridge immunological and neurological mechanisms, aligning with the presentation of
                <strong>fluctuating neuropathic pain, pruritus, autonomic instability, drug hypersensitivity, and inflammatory reactivity</strong>.
                These investigations would clarify whether mast-cell mediator release underlies, amplifies, or mimics autoimmune or neuro-inflammatory processes.
            </p>
            <h3>Request Summary</h3>
            <p>
                Kindly consider inclusion of these MCAS-specific mediator studies within the next diagnostic round or MDT review,
                to provide a more complete immunoneuro-inflammatory profile and identify any treatable mast-cell–driven component.
            </p>
            <h3>Referenced Blood Test Reports</h3>
            <ul>
                <li><a href="blood_tests/20-05-2025-Scanned-Letter-40157630_redacted.pdf" target="_blank">20 May 2025 – Blood Sciences (ANA, ENA, Immunoglobulins, Lyme, Complement)</a></li>
                <li><a href="blood_tests/21-05-2025-Scanned-Letter-40157721_redacted.pdf" target="_blank">21 May 2025 – Autoimmune & HLA-B27 Screening (Negative)</a></li>
                <li><a href="blood_tests/02-08-2025-Scanned-Letter-40162215_redacted.pdf" target="_blank">02 Aug 2025 – CSF Analysis & Pending Immunology (Preliminary)</a></li>
                <li><a href="blood_tests/04-08-2025-Scanned-Letter-40162434_redacted.pdf" target="_blank">04 Aug 2025 – CSF Microbiology (No Growth, Normal Glucose & Protein)</a></li>
                <li><a href="blood_tests/08-08-2025-Scanned-Letter-40162651_redacted.pdf" target="_blank">08 Aug 2025 – Serum ACE, MOG, and Aquaporin-4 Antibody Results (All Negative)</a></li>
                <li><a href="blood_tests/08-08-2025-Scanned-Letter-40162652_redacted.pdf" target="_blank">08 Aug 2025 – CSF Aquaporin-4 Antibodies (Negative)</a></li>
                <li><a href="blood_tests/08-08-2025-Scanned-Letter-40162684_redacted.pdf" target="_blank">08 Aug 2025 – Patient Summary Reference Page (Administrative)</a></li>
            </ul>
            <div class="note">
                <p><strong>Next step:</strong> Discuss with Dr Omar Malik or the Cromwell MDT whether these mast-cell mediator assays can be incorporated into upcoming laboratory orders or future multidisciplinary correlation review.</p>
            </div>
        </section>
        <section id="symptoms">
            <h2>Symptom Overview</h2>
            <p>Summary of symptom patterns and functional impact below.</p>
            <div class="table-wrap">
                <table>
                    <thead>
                        <tr>
                            <th>Category</th>
                            <th>Description</th>
                            <th>Functional Impact</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Throat & Facial Tension</strong></td>
                            <td>Left-sided throat and facial tightness, intermittent jaw and ear pressure, voice fatigue, and a persistent phlegm sensation (possible vagus nerve involvement).</td>
                            <td>Voice tires with extended conversation or reading aloud; meals and hydration are slower on high-symptom days; public speaking or long calls increase strain and recovery time.</td>
                        </tr>
                        <tr>
                            <td><strong>Leg, Foot & Groin</strong></td>
                            <td>Left calf heaviness, foot instability on uneven ground, intermittent tingling or numbness, groin and testicular pain, and pelvic floor tension (possible L4–S1 and pudendal/genitofemoral nerve involvement).</td>
                            <td>Walking distance and pace reduced during flares; balance and single-leg stance feel less secure on the left; sitting tolerance affected by pelvic discomfort; sexual comfort and function fluctuate.</td>
                        </tr>
                        <tr>
                            <td><strong>Upper Limb & Hand</strong></td>
                            <td>Left dorsal hand and wrist tingling with intermittent burning and pain that localises to the middle finger. Occasional wrist discomfort and reduced dexterity during flares.</td>
                            <td>Typing, gripping, utensil use, and other fine motor tasks are slower and fatigue quickly; handwriting and precision decrease during symptom peaks.</td>
                        </tr>
                        <tr>
                            <td><strong>Occipital & Scalp</strong></td>
                            <td>Patchy hair loss and regrowth within the occipital and posterior parietal scalp regions, correlating with greater, lesser, and third occipital nerve pathways (C2–C3). Features of occipital neuralgia with scalp allodynia. Full mapping and images are available in
                                <a href="https://jamessaint.github.io/medical/neurological/Occipital_Scalp_Changes_Nerve_Path_Mapping.html" target="_blank" rel="noopener">Occipital Scalp Changes - Nerve Path Mapping</a>.
                            </td>
                            <td>Fluctuating scalp sensitivity and pain may coincide with hair density changes; prolonged pressure on the back of the head or temperature shifts can increase discomfort; tension or paresthesia may extend into the neck or upper trapezius.</td>
                        </tr>
                        <tr>
                            <td><strong>Sensory & Pain</strong></td>
                            <td>Occipital area pain and pressure, intermittent facial and scalp paresthesia on the left, and occasional light-touch or temperature asymmetry. Central neuropathic pain overlay with peripheral triggers.</td>
                            <td>Sustained screen time, bright lighting, or head movements increase occipital pain; sleep can be disrupted, reducing next-day stamina; requires pacing and heat-based relief.</td>
                        </tr>
                        <tr>
                            <td><strong>Trigeminal-Occipital Convergence</strong></td>
                            <td>Persistent left-sided eyebrow-to-scalp pain radiating from the occipital region across the temple and into the cheek, with facial fullness and tingling. Distribution aligns with ophthalmic (V1) and maxillary (V2) trigeminal branches with possible occipital nerve interplay.</td>
                            <td>Discomfort behind the eye and across the brow; bending forward can accentuate facial heaviness; contributes to sensory overload, light sensitivity, and fatigue on high-symptom days.</td>
                        </tr>
                        <tr>
                            <td><strong>Visual & Vestibular</strong></td>
                            <td>Intermittent disturbance in the left visual field, eye strain, and dizziness with rapid head turns. Motion and visually busy environments increase symptoms.</td>
                            <td>Reading and multitasking are slower; prefers larger fonts and reduced motion; needs regular breaks and steady visual anchors for balance.</td>
                        </tr>
                        <tr>
                            <td><strong>Cognitive & Energy</strong></td>
                            <td>Mental fatigue, word-finding lapses, slower processing under cognitive load, and reduced stress tolerance, especially during flares.</td>
                            <td>Complex tasks benefit from chunking and written checklists; requires recovery time after demanding activity; decision quality drops when multitasking or overtired.</td>
                        </tr>
                        <tr>
                            <td><strong>Autonomic & General</strong></td>
                            <td>Fatigue disproportionate to effort, heart-in-throat sensations, and temperature intolerance during flares. Heightened reactivity to stress.</td>
                            <td>Benefits from calm start-up to demanding interactions, breathing resets, gentle pacing, and consistent daily rhythm; overstimulation prolongs recovery.</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </section>
        <!-- Footer -->
        <footer class="site-footer mt-4" role="contentinfo" aria-label="Site footer">
            <div class="footer-container text-center">
                <hr class="footer-rule" />
                <div class="footer-note mb-1">
                    Private & Confidential · Intended for the named clinical team and the patient only.
                </div>
                <div class="footer-copy">
                    © <span id="copy-year"></span> James Saint. All rights reserved.
                </div>
            </div>
        </footer>
        <!-- Year Autoupdate -->
        <script>
        (function() {
            var y = new Date().getFullYear();
            var el = document.getElementById('copy-year');
            if (el) el.textContent = y;
        })();
        </script>
    </main>
</body>

</html>